Novartis Lp(a) Drug Misses in First Late-Stage Outcomes Test

Novartis said its Ionis-partnered Lp(a)-lowering drug failed to reduce the risk of heart attack, stroke or other major cardiovascular events in a phase 3 trial, the first late-stage outcomes test of any therapy aimed at the lipoprotein(a) particle.

The drug industry's longest-running bet on a stubborn cholesterol-like particle has just taken its first real hit. Novartis said its lipoprotein(a)-lowering therapy, developed with partner Ionis, did not reduce the risk of heart attack, stroke or other major cardiovascular events in a phase 3 trial — the first time any drug built to attack Lp(a) has been tested to that standard and come back with an answer.

The result matters far beyond one compound. Every company working on Lp(a) has been operating on the same premise: that the particle is not merely a marker of risk but a cause of it, and that driving levels down should translate into fewer cardiovascular events. That premise has now been put to a randomized, late-stage test and has not been confirmed.

Why Lp(a) attracted so much capital in the first place

Lipoprotein(a) is a cholesterol-carrying particle in the blood whose level is set largely by genetics. Diet, exercise and statins barely move it. Large observational and genetic studies have long linked high Lp(a) to heart attacks, strokes and narrowed aortic valves, and roughly nothing on the market addresses it directly. That combination — a well-documented risk factor, a fixed patient population identifiable with a single blood test, and no approved treatment — made it one of the most attractive unclaimed targets in cardiovascular medicine.

The catch, always, was that association is not causation in the way a regulator or a payer means it. Lowering a number in a lab report is not the same as preventing a hospital admission. Cardiovascular drug development is littered with agents that moved a biomarker impressively and did nothing for patients. Investors accepted that risk because the genetic evidence for Lp(a) looked unusually strong. The phase 3 outcome reported by Fierce Biotech is the first hard data point on the other side of that argument.

What the miss does to the rest of the class

Novartis was first to a late-stage outcomes readout, which means it was also carrying the class-validating risk for everyone else. A clean win would have de-risked competing programs across the industry and turned Lp(a) testing into routine cardiology practice more or less overnight. A miss does the opposite work.

Rivals now face three uncomfortable questions at once. First, whether the failure is specific to this molecule — its mechanism, its dosing, the degree of Lp(a) reduction it achieved — or whether it indicts the target itself. Second, whether the trial enrolled the right patients: outcomes studies in cardiology live or die on baseline risk, background therapy and follow-up duration, and a population already well managed on statins and other agents leaves less room for any new drug to show benefit. Third, whether boards will keep funding multi-year outcomes trials in a target that has just produced its first negative headline.

Those questions will not be settled by a top-line statement. The full dataset — how much Lp(a) came down, in whom, and whether any subgroup moved — is what determines whether the class survives as a serious commercial proposition or shrinks to a niche pursued by one or two believers.

Where this leaves Novartis and Ionis financially

The two companies sit at very different points on the risk curve. For Novartis, a diversified large-cap with a broad marketed portfolio, a single failed cardiovascular outcomes trial is a costly disappointment and the loss of a potential blockbuster, not a threat to the business. Shares closed at 159.99 on Friday, 4 September 2026, down 1.90% on the day from a prior close of 163.09, having traded between 159.63 and 160.93.

Ionis, whose model is built on partnering antisense-derived medicines and collecting milestones and royalties, has a narrower base to absorb the news. Its stock finished at 58.09, essentially flat at -0.07%, off a 58.13 prior close and within a 57.78 to 58.96 range. Note the timing: those are last-trade prices as of 20:00 GMT on 4 September, before the trial result circulated widely. The market reaction, if there is one, is still ahead.

For context on the tape that day, the S&P 500 tracker closed at $770.19, down 0.39%; the Nasdaq 100 tracker at $718.96, up 0.18%; and the Dow tracker at $534.08, down 0.53%. Neither drug stock's move stood far outside a mildly negative session for large-cap equities.

What to watch from here

The near-term sequence is fairly predictable. Expect the detailed data at a major cardiology meeting, where the discussion will centre on the magnitude of Lp(a) reduction achieved and the event rates in each arm. Expect analysts to strip the Lp(a) franchise out of Novartis models and to revisit whatever milestone and royalty assumptions were embedded in Ionis valuations.

Longer term, three things determine whether this becomes a footnote or a turning point:

• Whether competing Lp(a) programs still in the clinic report anything that separates their mechanism or their patient selection from this trial.
• Whether cardiology guideline committees continue pushing routine Lp(a) measurement without a treatment that has proven outcomes benefit.
• Whether payers, already resistant to expensive preventive lipid therapies, treat the class as unproven by default.

There is also a broader lesson for biotech investors who have spent the past several years buying genetic-validation stories. Human genetics has become the industry's favourite de-risking tool: if nature has run the experiment, the argument goes, the drug is more likely to work. Lp(a) was among the strongest such cases in cardiovascular disease. A negative phase 3 here does not invalidate the approach, but it is a reminder that genetic association tells you about a lifetime of exposure, while a drug trial tests a few years of intervention in patients who already have disease. Those are different questions, and they can have different answers.

The unglamorous part of cardiovascular development

Outcomes trials are the most expensive and slowest studies in medicine — thousands of patients, years of follow-up, an endpoint that only accrues when people get sick. They are also the only evidence that changes practice. Companies chasing preventive cardiology have to accept that the biomarker phase is cheap and the proof phase is not, and that a decade of promising lipid data can be undone by one adjudicated event count.

Novartis and Ionis now have the first such count for Lp(a). Everyone else in the field has to decide how much of their own thesis it takes with it.

Key facts

• NVS last close: 159.99, -1.90%, as of 20:00 GMT, 4 Sep 2026
• IONS last close: 58.09, -0.07%, as of 20:00 GMT, 4 Sep 2026
• Trial outcome: No reduction in heart attack, stroke or other major cardiovascular events
• Significance: First phase 3 outcomes test of any Lp(a)-targeting drug

Frequently asked questions

What is lipoprotein(a) and why do drugmakers target it?

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in the blood whose level is set largely by inherited genetics rather than lifestyle. It is a known cardiovascular risk factor, linked in population and genetic studies to heart attacks and strokes. Statins and diet barely change it, and no approved therapy addresses it directly, which made it an attractive drug target.

What exactly did the Novartis trial show?

Novartis reported that its Lp(a)-lowering drug, developed with partner Ionis, failed to reduce patients' risk of heart attack, stroke or other major cardiovascular events in a phase 3 trial. It was the first late-stage test of any medicine designed to tackle Lp(a), so the result carries implications for the whole drug class, not just this compound.

Does this mean Lp(a) is not a real cardiovascular risk factor?

Not necessarily. Lp(a) remains a well-documented risk marker. The trial tested whether lowering it with this particular drug prevents events over the study period, which is a narrower question. A miss can reflect the molecule, the degree of Lp(a) reduction achieved, the patients enrolled or the follow-up length. Full data are needed to distinguish those explanations.

How did Novartis and Ionis shares perform?

As of the last trade at 20:00 GMT on 4 September 2026, NVS closed at 159.99, down 1.90% from a prior close of 163.09, with a day range of 159.63 to 160.93. IONS closed at 58.09, down 0.07% from 58.13, ranging between 57.78 and 58.96. Markets were closed at the time of writing.

What does the failure mean for competing Lp(a) programs?

Rivals lose the class validation a positive readout would have delivered. They must now argue that their mechanism, dosing or patient selection differs meaningfully from the failed trial. Funding decisions get harder, because Lp(a) outcomes studies require thousands of patients and years of follow-up, and boards may be less willing to underwrite that after a negative first result.

What should investors watch next?

The detailed dataset, likely presented at a cardiology conference, showing how far Lp(a) fell and how event rates compared between arms. Beyond that: whether analysts remove Lp(a) revenue from Novartis models, how Ionis milestone and royalty assumptions are revised, and whether guideline bodies and payers keep treating Lp(a) testing as clinically actionable without a proven therapy.

Sources

• Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial — Fierce Biotech

Photo: Los Muertos Crew · Pexels Licence — source